{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:48:47Z","timestamp":1794019727540,"version":"4.8.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","rheumatic.theclinics.com","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.rdc.2024.01.002","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T13:07:07Z","timestamp":1709644027000},"page":"161-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mimickers of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis"],"prefix":"10.1016","volume":"50","author":[{"given":"Jos\u00e9 A.","family":"G\u00f3mez-Puerta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Gente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamiko R.","family":"Katsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Leipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankti","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter H.","family":"van Binsbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Suarez-Almazor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Supplement_7","key":"10.1016\/j.rdc.2024.01.002_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez297","article-title":"Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy","volume":"58","author":"Abdel-Wahab","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2024.01.002_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","author":"Calabrese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2024.01.002_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102595","article-title":"Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort","volume":"19","author":"Roberts","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.rdc.2024.01.002_bib4","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105457","article-title":"Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer","volume":"90","author":"Melia","year":"2023","journal-title":"Joint Bone Spine"},{"issue":"4","key":"10.1016\/j.rdc.2024.01.002_bib6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.41587","article-title":"Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications","volume":"73","author":"Cappelli","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2024.01.002_bib7","article-title":"Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study","volume":"9","author":"Reid","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.rdc.2024.01.002_bib8","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed December 1, 2023."},{"issue":"5","key":"10.1016\/j.rdc.2024.01.002_bib9","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/rheumatology\/kez361","article-title":"An MRI study of immune checkpoint inhibitor-induced musculoskeletal manifestations myofasciitis is the prominent imaging finding","volume":"59","author":"Daoussis","year":"2020","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.rdc.2024.01.002_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jdiacomp.2008.09.004","article-title":"Charcot arthropathy of the foot and ankle: modern concepts and management review","volume":"23","author":"Wukich","year":"2009","journal-title":"J\u00a0Diabetes Complications"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/BOR.0b013e32835b4f3f","article-title":"Rheumatic manifestations of endocrine disease","volume":"25","author":"Chakravarty","year":"2013","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2024.01.002_bib12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/(SICI)1096-9136(199705)14:5<357::AID-DIA341>3.0.CO;2-8","article-title":"The natural history of acute Charcot\u2019s arthropathy in a diabetic foot specialty clinic","volume":"14","author":"Armstrong","year":"1997","journal-title":"Diabet Med"},{"key":"10.1016\/j.rdc.2024.01.002_bib13","doi-asserted-by":"crossref","first-page":"452","DOI":"10.7326\/0003-4819-54-3-452","article-title":"Identification of urate crystals in gouty synovial fluid","volume":"54","author":"McCarty","year":"1961","journal-title":"Ann Intern Med"},{"issue":"26","key":"10.1016\/j.rdc.2024.01.002_bib14","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1056\/NEJMra1511117","article-title":"Calcium Pyrophosphate Deposition Disease","volume":"374","author":"Rosenthal","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.rdc.2024.01.002_bib15","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jbspin.2018.01.009","article-title":"Crystal-induced oligoarthritis triggered by pembrolizumab, an immune checkpoint inhibitor","volume":"85","author":"Corominas","year":"2018","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s40425-019-0597-x","article-title":"Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare","volume":"7","author":"Kim","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.acra.2020.08.030","article-title":"Diagnostic Performance of Dual-energy CT Versus Ultrasonography in Gout: A Meta-analysis","volume":"29","author":"Shang","year":"2022","journal-title":"Acad Radiol"},{"issue":"6","key":"10.1016\/j.rdc.2024.01.002_bib18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M16-0570","article-title":"Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.rdc.2024.01.002_bib23","doi-asserted-by":"crossref","first-page":"MMT30","DOI":"10.2217\/mmt-2019-0005","article-title":"Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management","volume":"6","author":"Simeone","year":"2019","journal-title":"Melanoma Manag"},{"issue":"8","key":"10.1016\/j.rdc.2024.01.002_bib24","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.amjmed.2003.09.045","article-title":"Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome","volume":"116","author":"Davidson","year":"2004","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.rdc.2024.01.002_bib25","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.3390\/curroncol29070370","article-title":"Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists","volume":"29","author":"Druce","year":"2022","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.rdc.2024.01.002_bib27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/OTT.S57335","article-title":"Ipilimumab in the treatment of metastatic melanoma: management of adverse events","volume":"7","author":"Della Vittoria Scarpati","year":"2014","journal-title":"OncoTargets Ther"},{"issue":"5","key":"10.1016\/j.rdc.2024.01.002_bib28","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.3390\/curroncol30050355","article-title":"Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review","volume":"30","author":"Mallio","year":"2023","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010246","article-title":"Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario","volume":"15","author":"Spagnolo","year":"2022","journal-title":"Cancers"},{"issue":"10397","key":"10.1016\/j.rdc.2024.01.002_bib30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.rdc.2024.01.002_bib31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4239\/wjd.v2.i5.59","article-title":"Charcot osteoarthropathy in diabetes: A brief review with an emphasis on clinical practice","volume":"2","author":"Gouveri","year":"2011","journal-title":"World J Diabetes"},{"issue":"6","key":"10.1016\/j.rdc.2024.01.002_bib32","first-page":"622","article-title":"Prevalence of hand syndromes among patients with diabetes mellitus in Taiwan: A population-based study","volume":"9","author":"Hou","year":"2017","journal-title":"J\u00a0Diabetes"},{"issue":"6","key":"10.1016\/j.rdc.2024.01.002_bib33","first-page":"628","article-title":"Relationship between limited joint mobility of the hand and diabetic foot risk in patients with type 2 diabetes","volume":"9","author":"Mineoka","year":"2017","journal-title":"J\u00a0Diabetes"},{"issue":"6","key":"10.1016\/j.rdc.2024.01.002_bib34","first-page":"542","article-title":"Upper extremity arthropathy in diabetes","volume":"9","author":"Bloomgarden","year":"2017","journal-title":"J\u00a0Diabetes"},{"issue":"11","key":"10.1016\/j.rdc.2024.01.002_bib35","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.rdc.2024.01.002_bib36","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.2337\/dc18-2518","article-title":"T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors","volume":"42","author":"Yoneda","year":"2019","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1016\/j.rdc.2024.01.002_bib37","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1056\/NEJMra071714","article-title":"Sarcoidosis","volume":"357","author":"Iannuzzi","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.rdc.2024.01.002_bib38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/MCP.0000000000000715","article-title":"Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors","volume":"26","author":"Arkema","year":"2020","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/MOH.0000000000000301","article-title":"Mechanism of granuloma formation in sarcoidosis","volume":"24","author":"Sakthivel","year":"2017","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00002281-200401000-00010","article-title":"Rheumatologic manifestations of sarcoidosis","volume":"16","author":"Abril","year":"2004","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2024.01.002_bib41","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/acr.22737","article-title":"Clinical Characteristics of Sarcoid Arthropathy: A Population-Based Study","volume":"68","author":"Ungprasert","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2024.01.002_bib42","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejca.2021.05.041","article-title":"Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation","volume":"158","author":"Chanson","year":"2021","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.rdc.2024.01.002_bib43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2217\/imt-2020-0272","article-title":"Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis","volume":"13","author":"Kim","year":"2021","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.rdc.2024.01.002_bib44","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/0049-0172(86)90045-4","article-title":"Palmar fasciitis and arthritis with malignant neoplasms: a paraneoplastic syndrome","volume":"16","author":"Pfinsgraff","year":"1986","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.semarthrit.2014.03.005","article-title":"Palmar fasciitis and polyarthritis syndrome-systematic literature review of 100 cases","volume":"44","author":"Manger","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF02231700","article-title":"Palmar fasciitis and polyarthritis syndrome is multicausal","volume":"15","author":"Fernandez-Nebro","year":"1996","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2024.01.002_bib47","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11926-017-0690-4","article-title":"Pancreatic Panniculitis and Polyarthritis","volume":"19","author":"Zundler","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.rdc.2024.01.002_bib48","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12885-016-2184-6","article-title":"Pancreatic panniculitis in a patient with pancreatic-type acinar cell carcinoma of the liver--case report and review of literature","volume":"16","author":"Zundler","year":"2016","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.rdc.2024.01.002_bib49","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s10067-020-05333-8","article-title":"Clinical characteristics, treatment, and outcome of pancreatitis, panniculitis, and polyarthritis syndrome: a case-based review","volume":"40","author":"Betrains","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2024.01.002_bib50","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4103\/jcrt.jcrt_2386_21","article-title":"Pancreatic carcinoma presented with panniculitis and polyarthritis: A rare case","volume":"17","author":"Pan","year":"2021","journal-title":"J\u00a0Cancer Res Ther"},{"issue":"4","key":"10.1016\/j.rdc.2024.01.002_bib51","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1111\/ajd.12842","article-title":"Pancreatic panniculitis: A case series from a tertiary university hospital in Spain","volume":"59","author":"Fern\u00e1ndez-Sartorio","year":"2018","journal-title":"Australas J Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2024.01.002_bib52","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1038\/modpathol.3800686","article-title":"Nonductal neoplasms of the pancreas","volume":"20","author":"Klimstra","year":"2007","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.rdc.2024.01.002_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24031982","article-title":"Eosinophilic Fasciitis: Current and Remaining Challenges","volume":"24","author":"Mazilu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.rdc.2024.01.002_bib54","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.diii.2014.06.018","article-title":"Eosinophilic fasciitis: typical abnormalities, variants and differential diagnosis of fasciae abnormalities using MR imaging","volume":"96","author":"Kirchgesner","year":"2015","journal-title":"Diagn Interv Imaging"},{"issue":"4\u20135","key":"10.1016\/j.rdc.2024.01.002_bib55","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.autrev.2014.01.019","article-title":"Diagnosis and classification of eosinophilic fasciitis","volume":"13","author":"Pinal-Fernandez","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.rdc.2024.01.002_bib56","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/1346-8138.14160","article-title":"Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis","volume":"45","author":"Jinnin","year":"2018","journal-title":"J\u00a0Dermatol"},{"issue":"10","key":"10.1016\/j.rdc.2024.01.002_bib57","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s00431-002-1038-1","article-title":"Eosinophilic fasciitis leading to painless contractures","volume":"161","author":"Huppke","year":"2002","journal-title":"Eur J Pediatr"},{"issue":"18","key":"10.1016\/j.rdc.2024.01.002_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184450","article-title":"Morphea, Eosinophilic Fasciitis and Cancer: A Scoping Review","volume":"15","author":"Joly-Chevrier","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.rdc.2024.01.002_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ph16020259","article-title":"Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics","volume":"16","author":"Macklin","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"36","key":"10.1016\/j.rdc.2024.01.002_bib60","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007985","article-title":"Secondary hypertrophic osteoarthropathy caused by non-pleural or pulmonary tumors","volume":"96","author":"Meyer","year":"2017","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.rdc.2024.01.002_bib61","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1016\/j.cllc.2020.01.004","article-title":"Clinical Course of Hypertrophic Pulmonary Osteoarthropathy in a Patient Receiving Immune Checkpoint Inhibitor Therapy","volume":"21","author":"Johns","year":"2020","journal-title":"Clin Lung Cancer"},{"issue":"Suppl 7","key":"10.1016\/j.rdc.2024.01.002_bib62","doi-asserted-by":"crossref","first-page":"vii68","DOI":"10.1093\/rheumatology\/kez295","article-title":"Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy","volume":"58","author":"Kostine","year":"2019","journal-title":"Rheumatology"},{"issue":"3\u20134","key":"10.1016\/j.rdc.2024.01.002_bib63","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/14017439409099120","article-title":"Lung cancer containing growth hormone-releasing hormone associated with hypertrophic osteoarthropathy. Case report","volume":"28","author":"Nomori","year":"1994","journal-title":"Scand J Thorac Cardiovasc Surg"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib64","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/ard.42.1.98","article-title":"Pachydermoperiostosis: scintigraphic, thermographic, plethysmographic, and capillaroscopic observations","volume":"42","author":"Fam","year":"1983","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2024.01.002_bib65","series-title":"Textbook of Rheumatology","first-page":"1514","article-title":"Hypertrophic osteoarthropathy","author":"Altman","year":"1997"},{"issue":"3","key":"10.1016\/j.rdc.2024.01.002_bib66","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00296-010-1667-z","article-title":"Primary hypertrophic osteoarthropathy","volume":"32","author":"Poormoghim","year":"2012","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.rdc.2024.01.002_bib67","first-page":"626","article-title":"The spectrum of soft tissue and skeletal abnormalities of hypertrophic osteoarthropathy","volume":"17","author":"Pineda","year":"1990","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2024.01.002_bib68","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12149-010-0344-3","article-title":"Hypertrophic osteoarthropathy manifested with isolated calcaneal periostitis in bone scintigraphy","volume":"24","author":"Moralidis","year":"2010","journal-title":"Ann Nucl Med"},{"issue":"3","key":"10.1016\/j.rdc.2024.01.002_bib69","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1159\/000512818","article-title":"A\u00a0Case of Lung Adenocarcinoma with Pulmonary Hypertrophic Osteoarthropathy Showing Pathological Complete Response to a Pembrolizumab-Containing Chemoimmunotherapy","volume":"14","author":"Kataoka","year":"2021","journal-title":"Case Rep Oncol"},{"issue":"8","key":"10.1016\/j.rdc.2024.01.002_bib70","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clml.2023.04.008","article-title":"POEMS Syndrome-Clinical Picture and Management. Current Knowledge","volume":"23","author":"Jurczyszyn","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.rdc.2024.01.002_bib71","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood-2007-12-126979","article-title":"Restrictive usage of monoclonal immunoglobulin lambda light chain germline in POEMS syndrome","volume":"112","author":"Abe","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.rdc.2024.01.002_bib72","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood-2002-07-2299","article-title":"POEMS syndrome: definitions and long-term outcome","volume":"101","author":"Dispenzieri","year":"2003","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.rdc.2024.01.002_bib73","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1182\/blood-2011-06-362392","article-title":"The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome","volume":"118","author":"D\u2019Souza","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.rdc.2024.01.002_bib74","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ccr3.528","article-title":"The first case of POEMS syndrome with synchronous breast cancer: What are the associated diagnostic challenges?","volume":"4","author":"Hiyama","year":"2016","journal-title":"Clin Case Rep"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib75","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41572-021-00317-7","article-title":"Castleman disease","volume":"7","author":"Carbone","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.rdc.2024.01.002_bib76","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2133.1964.tb14541.x","article-title":"An acute febrile neutrophilic dermatosis","volume":"76","author":"Sweet","year":"1964","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib77","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0738-081X(93)90112-P","article-title":"Sweet\u2019s syndrome and cancer","volume":"11","author":"Cohen","year":"1993","journal-title":"Clin Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.002_bib78","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-2-34","article-title":"Sweet\u2019s syndrome \u2013 a comprehensive review of an acute febrile neutrophilic dermatosis","volume":"2","author":"Cohen","year":"2007","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.rdc.2024.01.002_bib79","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3892\/ijo.2013.1874","article-title":"Insight into Sweet\u2019s syndrome and associated-malignancy: a review of the current literature","volume":"42","author":"Raza","year":"2013","journal-title":"Int J Oncol"},{"issue":"2","key":"10.1016\/j.rdc.2024.01.002_bib80","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2230.2005.01996.x","article-title":"Cutaneous manifestations of granulocyte colony-stimulating factor","volume":"31","author":"White","year":"2006","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.rdc.2024.01.002_bib81","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1085-5629(05)80015-X","article-title":"Sweet syndrome: acute febrile neutrophilic dermatosis","volume":"14","author":"Su","year":"1995","journal-title":"Semin Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2024.01.002_bib82","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.1889449","article-title":"\u201cSkin rashes\u201d and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management","volume":"18","author":"Sollena","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.rdc.2024.01.002_bib83","first-page":"1024","article-title":"Pembrolizumab-Induced Neutrophilic Dermatosis of the Dorsal Hands","volume":"3","author":"Mayer","year":"2020","journal-title":"Oncol Case Report J"},{"issue":"5","key":"10.1016\/j.rdc.2024.01.002_bib84","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13074","article-title":"Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review","volume":"32","author":"Ravi","year":"2019","journal-title":"Dermatol Ther"},{"issue":"7","key":"10.1016\/j.rdc.2024.01.002_bib85","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1177\/1078155220906885","article-title":"Sweet\u2019s syndrome under ipilimumab therapy and a brief comparison of the cases in literature","volume":"26","author":"Ya\u015far","year":"2020","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"2","key":"10.1016\/j.rdc.2024.01.002_bib86","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1024\/0301-1526\/a000675","article-title":"Erythromelalgia","volume":"47","author":"Klein-Weigel","year":"2018","journal-title":"Vasa."},{"issue":"3","key":"10.1016\/j.rdc.2024.01.002_bib87","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archderm.136.3.330","article-title":"Natural history of erythromelalgia: presentation and outcome in 168 patients","volume":"136","author":"Davis","year":"2000","journal-title":"Arch Dermatol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X24000024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X24000024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T19:54:50Z","timestamp":1713988490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X24000024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0889857X24000024"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2024.01.002","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mimickers of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2024.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}